前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描与多参数磁共振成像在前列腺癌生化复发检测中的头对头比较:系统评价与荟萃分析
本荟萃分析纳入6项研究共290例患者,直接比较PSMA PET/CT与mpMRI检测前列腺癌生化复发的诊断效能。PSMA PET/CT与mpMRI的总体检出率分别为0.69(95%CI 0.45-0.89)和0.70(95%CI 0.44-0.91),两者无显著差异(P=0.95);局部复发和淋巴结转移检出率亦无统计学显著差异(P=0.55、0.23)。作者认为两者表现似乎相当,但纳入研究样本量不大,未来需更广泛研究。
要点
- PSMA PET/CT与mpMRI检测前列腺癌生化复发的总体检出率分别为0.69和0.70,无显著差异(P=0.95)。
- 局部复发检出率PSMA PET/CT 0.52 vs mpMRI 0.62,淋巴结转移检出率PSMA PET/CT 0.50 vs mpMRI 0.32,均无统计学显著差异(P=0.55、0.23)。
- 作者认为两者诊断效能似乎相当,但纳入研究样本量不大,未来需更广泛研究。
核心结论
- PSMA PET/CT与mpMRI在识别前列腺癌生化复发方面表现似乎相当,但荟萃分析结果来自样本量不大的研究,未来应开展更广泛的研究。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、Embase和Web of Science截至2023年3月的文献,纳入6项直接比较PSMA PET/CT与mpMRI检测前列腺癌生化复发的研究,共290例患者,采用QUADAS-2工具评估方法学质量。
诊断标准与关键数值
- PSMA PET/CT总体检出率为0.69(95%CI 0.45-0.89),mpMRI为0.70(95%CI 0.44-0.91),两者无显著差异(P=0.95)。
- 局部复发检出率PSMA PET/CT为0.52(95%CI 0.39-0.65),mpMRI为0.62(95%CI 0.31-0.89),无统计学显著差异(P=0.55)。
- 淋巴结转移检出率PSMA PET/CT为0.50(95%CI 0.26-0.74),mpMRI为0.32(95%CI 0.18-0.48),无统计学显著差异(P=0.23)。
临床应用与阅片要点
- 作者认为PSMA PET/CT与mpMRI在检测前列腺癌生化复发方面表现似乎相当,但原文未据此给出具体临床应用推荐。
局限性
- 荟萃分析结果来自样本量不大的研究(共6项研究、290例患者)。
- 作者指出未来应开展更广泛的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: Our main goal of this meta-analytical analysis was to evaluate the diagnostic effectiveness of prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) against multiparametric magnetic resonance imaging (mpMRI) in the context of identifying biochemical recurrence in patients with prostate cancer (PCa).
MATERIALS AND METHODS: A thorough search covering articles published until March 2023 was carried out across major databases such as PubMed, Embase, and Web of Science. Studies examining the direct comparison of PSMA PET/CT and mpMRI in patients with PCa suffering biochemical recurrence were included in the inclusion criteria. Using the renowned Quality Assessment of Diagnostic Performance Studies-2 technique, each study's methodological rigor was assessed.
RESULTS: We analyzed data from six eligible studies involving 290 patients in total. The combined data showed that for PSMA PET/CT and mpMRI, respectively, the pooled overall detection rates for recurrent PCa after definitive treatment were 0.69 (95% confidence interval [CI]: 0.45-0.89) and 0.70 (95% CI: 0.44-0.91). The detection rates for local recurrence were specifically 0.52 (95% CI: 0.39-0.65) and 0.62 (95% CI: 0.31-0.89), while they were 0.50 (95% CI: 0.26-0.74) and 0.32 (95% CI: 0.18-0.48) for lymph node metastasis. Notably, there was no discernible difference between the two imaging modalities in terms of the overall detection rate (P = 0.95). The detection rates for local recurrence and lymph node metastasis did not differ statistically significantly (P = 0.55, 0.23).
CONCLUSION: The performance of PSMA PET/CT and mpMRI in identifying biochemical recurrence in PCa appears to be comparable. However, the meta-analysis' findings came from research with modest sample sizes. In this context, more extensive research should be conducted in the future.
引用
- Jiang Z, Yang T, Xu L, et al. Head-to-head comparison of prostate-specific membrane antigen positron emission tomography/computed tomography and multiparametric magnetic resonance imaging in the detection of biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Clin Radiol. 2024. PMID: 38582633. doi:10.1016/j.crad.2024.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。